Jamjoom Pharma FY profit 463.8M riyals, +30% y/y

Jamjoom Pharma FY profit 463.8M riyals, +30% y/y

Jamjoom Pharma Reports 30% Year-Over-Year Profit Growth in Fiscal Year 2025

Jamjoom Pharma (JSE: JPH) has announced a net profit of SAR 463.8 million for the fiscal year ending December 2025, representing a 30% year-over-year (YoY) increase. This growth follows a previously reported 30% surge in net profit to SAR 396 million in the corresponding period of 2024, underscoring the company's sustained financial momentum.

The latest results, detailed in the company's annual report, highlight Jamjoom Pharma's ability to navigate market dynamics while expanding its operational performance. The pharmaceutical sector has faced broader challenges in 2025, including raw material cost fluctuations and regulatory shifts, yet Jamjoom Pharma's profit growth outpaces many industry peers.

The company's full-year earnings reflect a combination of strategic operational adjustments and demand resilience across its product portfolio. However, specific drivers of the 30% YoY increase, such as revenue contributions from key therapeutic segments or geographic regions, were not disclosed in the publicly available summaries of the annual report.

Investors may note that the October 2025 press release emphasized a SAR 396 million profit figure, which likely corresponds to a quarterly or interim update rather than the full fiscal year. The finalized annual report provides the comprehensive SAR 463.8 million figure, aligning with the company's year-end financial disclosure.

With its latest performance, Jamjoom Pharma reinforces its position as a key player in Saudi Arabia's pharmaceutical landscape. The company has not yet provided guidance for fiscal year 2026.

(https://portalvhds1fxb0jchzgjph.blob.core.windows.net/press-releases-attachments./3931350/903_16392_4526_2025-10-22_20-42-56_en.pdf): Jamjoom Pharma press release, October 22, 2025.
(https://investors.jamjoompharma.com/media/vxan40lu/annual-report-2024.pdf): Jamjoom Pharma Annual Report 2024, as referenced in investor relations materials.

This article relies exclusively on the provided source materials and does not incorporate external data or projections.